3No authors listed. Intensive blood-glucose control with sulpho-nylureas or insulin compared with conventional treatment and risk ofcomplications in patients with type 2diabetes ( UKPDS 33). UK Pro-spective Diabetes Study(UKPDS) Group. Lancet 1998 ;352?9131):837-853.
4Meier JJ,Gallwitz B ,Nauck MA. Glucagon-like peptide 1 andgastric inhibitory polypeptide : potential applications in type 2 diabetesmellitus. Biodrugs 2003; 17(2) :93-102.
5McIntosh CH, Demuth HU, Pospisilik JA, et al. Dipeptidylpeptidase IV inhibitors : how do they work as new antidiabetic agents .Regul Pept 2005; 128(2) :159-165.
6Holst JJ. Glucagon-like peptide-1 : from extract to agent. TheClaude Bernard Lecture,2005. Diabetologia 2006;49(2) :253-260.
7Baggio L L, Drucker D J. Biology of incretins?? GLP-1 andGIP. Gastroenterology 2007; 132(6) :2131-2157.
8Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data andclinical implications. Diabetes Care 2007 ;30(6) :1344-1350.
9Scheen A J. Pharmacokinetics of dipeptidylpeptidase-4 inhibi-tors. Diabetes Obes Metab 2010;12(8) :648-658.
